TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
AI Agents · Agentic clinical trial workforce replaces 50% of CRO human labor, targets 100% in 2 years
now playing · AI Agents
AI in Healthcaretailwindscore 9/10pedro coelho
Clinical trial automation OS cuts 12-year drug development to 6 years at half cost
Biorce's AI operating system automates the clinical trial protocol lifecycle — from molecule viability simulation to protocol generation to study design optimization — reducing the median $…
Enterprise AI Adoptiontailwindscore 9/10pedro coelho
Pharma adopts AI clinical trial software at $250K-$10M+ ACV with 3-5 year commitments
Large pharma companies are signing multi-year contracts (70% 3-year, now piloting 5-year) for Biorce's platform at 250K-10M+ EUR base subscriptions plus usage fees. The buying trigger is re…
AI Agentstailwindscore 8/10pedro coelho
Agentic clinical trial workforce replaces 50% of CRO human labor, targets 100% in 2 years
Biorce's 'true agentic workforce' coordinates specialized agents for protocol generation, study design, patient simulation, regulatory strategy, and economic optimization. Currently replace…
AI Infrastructuretailwindscore 8/10pedro coelho
Model orchestration layer routes clinical tasks to specialized proprietary and frontier models
Biorce built a model orchestrator that decomposes clinical trial workflows into discrete tasks (protocol writing, statistical analysis, 3D molecule visualization, regulatory compliance) and…
Data Center Infrastructuretailwindscore 8/10pedro coelho
Multi-cloud single-tenant deployment with push-only model updates solves pharma data sovereignty
Biorce deploys dedicated Kubernetes clusters in each client's cloud account (AWS/Azure/GCP) with a 'data lakehouse' architecture (Databricks/Snowflake) where model updates are pushed but da…
AI Economics & Business Modelstailwindscore 8/10pedro coelho
Hybrid subscription + usage pricing captures 10-20% of $120B CRO market value
Biorce's pricing formula (based on trial count, molecules, headcount) yields 250K-10M+ EUR base ARR per client with usage overages. At 150 trials/year for large pharma, this scales to 100M+…
Tech Regulation & Antitrusttailwindscore 7/10pedro coelho
EU AI Act and EMA regulatory readiness become competitive moats for clinical AI
European pharma buyers require Business Continuity Plans (3-5 year runway) and auditability of AI training data flows. Biorce's single-tenant architecture with auditor-accessible training l…
Venture Capitalmixedscore 7/10pedro coelho
Deep tech fundraising requires 232 meetings for pre-seed; Series A inbound after hypergrowth proof
Biorce's pre-seed required 232 investor meetings over 5 months (12 term sheets) due to category ambiguity (SaaS vs healthtech vs biotech). Series A was inbound from Norsken/DST after 0-to-$…